Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice
Sam D. Molyneux, … , Lawrence S. Kirschner, Rama Khokha
Sam D. Molyneux, … , Lawrence S. Kirschner, Rama Khokha
Published August 9, 2010
Citation Information: J Clin Invest. 2010;120(9):3310-3325. https://doi.org/10.1172/JCI42391.
View: Text | PDF
Research Article Oncology

Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice

  • Text
  • PDF
Abstract

Some cancers have been stratified into subclasses based on their unique involvement of specific signaling pathways. The mapping of human cancer genomes is revealing a vast number of somatic alterations; however, the identification of clinically relevant molecular tumor subclasses and their respective driver genes presents challenges. This information is key to developing more targeted and personalized cancer therapies. Here, we generate a new mouse model of genomically unstable osteosarcoma (OSA) that phenocopies the human disease. Integrative oncogenomics pinpointed cAMP-dependent protein kinase type I, α regulatory subunit (Prkar1a) gene deletions at 11qE1 as a recurrent genetic trait for a molecularly distinct subclass of mouse OSA featuring RANKL overexpression. Using mouse genetics, we established that Prkar1a is a bone tumor suppressor gene capable of directing subclass development and driving RANKL overexpression during OSA tumorigenesis. Finally, we uncovered evidence for a PRKAR1A-low subset of human OSA with distinct clinical behavior. Thus, tumor subclasses develop in mice and can potentially provide information toward the molecular stratification of human cancers.

Authors

Sam D. Molyneux, Marco A. Di Grappa, Alexander G. Beristain, Trevor D. McKee, Daniel H. Wai, Jana Paderova, Meenakshi Kashyap, Pingzhao Hu, Tamara Maiuri, Swami R. Narala, Vuk Stambolic, Jeremy Squire, Josef Penninger, Otto Sanchez, Timothy J. Triche, Geoffrey A. Wood, Lawrence S. Kirschner, Rama Khokha

×

Figure 6

Deregulated PKA signaling drives RANKL overexpression during OSA development.

Options: View larger image (or click on image) Download as PowerPoint
Deregulated PKA signaling drives RANKL overexpression during OSA develop...
(A) H&E staining of (left) OSA in Prkar1aΔOB/+/MOTO+ tibia and (right) tumor-free femur from age-matched MOTO+ mouse. (B) qPCR of SV40 TAg in samples from 3- to 4-week-old mice. (C) qPCR of RANKL RNA in bone samples of 3- to 4-week-old MOTO+ and Prkar1aΔOB/+/MOTO+ mice and tumor cell lines from Prkar1aΔOB/+/MOTO+ mice (rib, 8R1 and 17R2; skull, 17S1), moto2.1, and control MC-3T3 and 7F2-OSB cells. (D) Serum RANKL analysis by ELISA in 3- to 4-week-old mice of indicated genotypes. F, femur; R, rib; T, tibia; Tumors, rib and tibia. (B–D) Numbers identify the same individual mice across panels. (E) Western blots showing total and phospho-CREB protein in cell lines derived from Prkar1aΔOB/+/MOTO+ bone tumors and MC3T3 cells and (F) tumors from the indicated genotypes. Endogenous actin was used as protein loading control. (G) Phospho-CREB immunostaining of femurs of control mice of the indicated genotypes (WT, Prkar1aΔOB/+, and MOTO+ mice), and a skull tumor from a Prkar1aΔOB/+/MOTO+ mouse. Arrows highlight cells with low phospho-CREB staining; strong staining appears in the tumor. (H) Genomic PCR for CRE-mediated floxed exon 2 deletion in primary osteoblast cultures from Prkar1afl/+ mouse bones treated with recombinant adenoviral CRE-GFP or control GFP expression construct. (I) PKA activity from Adeno-Cre/GFP– or GFP-treated primary osteoblasts cultured from Prkar1afl/+ bones was measured either in the absence of exogenous cAMP (free PKA activity) or in the presence of 25 μM cAMP (total PKA). Scale bars: 150 μm (A); 50 μm (A, insets, and G). Data are represented as mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts